*Data come from a randomized (1:1:1), controlled, subject-and-assessor-masked, prospective trial. DFT015 was superior to Symfonyd (~31% difference; 97.5% CI 13.34, 46.79) and AT LARA‡(~30% differences; 97.5% CI 12.54, 46.68). †AcrySof IQ Vivity®was tested. AcrySof IQ Vivi...